Literature DB >> 34964997

Engineering Radiosensitizer-Based Metal-Phenolic Networks Potentiate STING Pathway Activation for Advanced Radiotherapy.

Jie Yan1,2, Guohao Wang1,2, Lisi Xie1,2, Hao Tian1,2, Jie Li1,2, Bei Li1,2, Wei Sang1,2, Wenxi Li1,2, Zhan Zhang1,2, Yunlu Dai1,2.   

Abstract

Radiotherapy, a mainstay of first-line cancer treatment, suffers from its high-dose radiation-induced systemic toxicity and radioresistance caused by the immunosuppressive tumor microenvironment. The synergy between radiosensitization and immunomodulation may overcome these obstacles for advanced radiotherapy. Here, the authors propose a radiosensitization cooperated with stimulator of interferon genes (STING) pathway activation strategy by fabricating a novel lanthanide-doped radiosensitizer-based metal-phenolic network, NaGdF4 :Nd@NaLuF4 @PEG-polyphenol/Mn (DSPM). The amphiphilic PEG-polyphenol successfully coordinates with NaGdF4 :Nd@NaLuF4 (radiosensitizer) and Mn2+ via robust metal-phenolic coordination. After cell internalization, the pH-responsive disassembly of DSPM triggers the release of their payloads, wherein radiosensitizer sensitizes cancer cells to X-ray and Mn2+ promote STING pathway activation. This radiosensitizer-based DSPM remarkably benefits dendritic cell maturation, anticancer therapeutics in primary tumors, accompanied by robust systemic immune therapeutic performance against metastatic tumors. Therefore, a powerful radiosensitization with STING pathway activation mediated immunostimulation strategy is highlighted here to optimize cancer radiotherapy.
© 2022 Wiley-VCH GmbH.

Entities:  

Keywords:  lanthanide-doped radiosensitizers; manganese; metal-phenolic networks; radiosensitization effects; stimulator of interferon genes pathways

Mesh:

Substances:

Year:  2022        PMID: 34964997     DOI: 10.1002/adma.202105783

Source DB:  PubMed          Journal:  Adv Mater        ISSN: 0935-9648            Impact factor:   30.849


  2 in total

1.  Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy.

Authors:  Pengkai Wu; Haitian Zhang; Yin Yin; Meiling Sun; Shuai Mao; Huihui Chen; Yexuan Deng; Shuai Chen; Shuo Li; Beicheng Sun
Journal:  Adv Sci (Weinh)       Date:  2022-03-25       Impact factor: 17.521

2.  A protein-based cGAS-STING nanoagonist enhances T cell-mediated anti-tumor immune responses.

Authors:  Xuan Wang; Yingqi Liu; Chencheng Xue; Yan Hu; Yuanyuan Zhao; Kaiyong Cai; Menghuan Li; Zhong Luo
Journal:  Nat Commun       Date:  2022-09-28       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.